More than 90% of CML occurrences are associated with a translocation between (9;22) (q34; q11) to form the Philadelphia (Ph) chromosome and the BCR::ABL fusion gene at the molecular level. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.